Related Experiment Videos
Behavioral tests after intracerebral hemorrhage in the rat.
Ya Hua1, Timothy Schallert, Richard F Keep
1Department of Neurosurgery, University of Michigan, Ann Arbor 48109-0532, USA. yahua@umich.edu
Stroke
|October 5, 2002
Summary
Intracerebral hemorrhage (ICH) in rats causes neurological deficits that improve over four weeks. Specific blood components contribute to these deficits, offering targets for therapeutic intervention.
Area of Science:
- Neuroscience
- Pathology
- Animal Models
Background:
- Intracerebral hemorrhage (ICH) in humans leads to significant brain swelling and neurological impairment.
- A rat model of ICH is crucial for studying edema but requires behavioral outcome assessment.
- Understanding the temporal dynamics of ICH pathology and neurological deficits is vital for preclinical research.
Purpose of the Study:
- To evaluate sensorimotor deficits in a rat ICH model using a battery of behavioral tests.
- To identify specific hematoma components responsible for ICH-induced neurological impairments.
- To correlate behavioral outcomes with edema formation over time.
Main Methods:
- Utilized forelimb placing, forelimb preference, and corner turn tests to assess sensorimotor function.
- Administered autologous whole blood, blood components (packed red blood cells, thrombin), hirudin, or saline to rats.
- Monitored behavioral performance from day 1 to day 28 post-ICH induction.
Main Results:
- Significant neurological deficits were observed by day 1 post-ICH, with gradual functional recovery over 4 weeks.
- Forelimb placing scores correlated with perihematomal edema changes.
- Thrombin exacerbated deficits, while hirudin mitigated them; packed red blood cells induced delayed deficits.
Conclusions:
- Behavioral tests provide continuous monitoring of neurological deficits and aid in evaluating therapeutic strategies for ICH.
- The time course of neurological deficits aligns with cerebral edema development in ICH models.
- Functional recovery after ICH presents opportunities for therapeutic development.